Pancreatic Cancer Action Network Inc.

11/18/2026 | Press release | Distributed by Public on 11/18/2026 08:48

Research Spotlight: Why This Awareness Month Feels Different

Editor's note: The "Research Spotlight" series is written by Dr. Anna Berkenblit, PanCAN's Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and research in pancreatic cancer. Follow Dr. Berkenblit on X and LinkedIn.

Every November, the pancreatic cancer community comes together - in purple - to recognize Pancreatic Cancer Awareness Month. It's a time to honor those we've lost, celebrate survivors and remind the world that this disease demands urgency.

The numbers still sting. In 2026, an estimated 67,530 Americans will be diagnosed with pancreatic cancer, and 52,740 are expected to die from the disease. The five-year survival rate has stalled at 13% for the third year in a row - and it's just 8% for people diagnosed with pancreatic adenocarcinoma, the most common type. Pancreatic cancer remains the only major cancer with a five-year survival rate below 20%.

But this Awareness Month feels different. For the first time, we can point to a therapy designed specifically to target the biology that drives nearly all pancreatic tumors - and it's already reaching patients. In this Spotlight, I'll share why knowing your risk and the warning signs matters, where we stand on early detection and treatment and the work still ahead to turn this momentum into longer, better lives for everyone facing this disease.

Know Your Risk, Know the Signs

The single most powerful thing any of us can do this month is learn the risk factors and symptoms of pancreatic cancer - and share them with the people we love.

Risk factors include smoking, obesity, alcohol, age, a family history of pancreatic cancer, chronic or hereditary pancreatitis and long-standing diabetes. About 10% of pancreatic cancers are linked to an inherited mutation, also known as germline mutation, such as in the BRCA1 or BRCA2 genes. If pancreatic cancer runs in your family, PanCAN strongly recommends meeting with a genetic counselor to discuss genetic testing for inherited mutations and whether you may be eligible for a screening program.

Early symptoms are easy to miss or mistake for something else. They can include:

  • Pain in the abdomen and/or mid-to-upper back
  • Jaundice (yellowing of the skin and eyes)
  • Unexplained weight loss
  • Loss of appetite or nausea
  • Changes in stool (oily or watery)
  • New-onset diabetes

Diabetes can be both a risk factor and a symptom. People diagnosed with new-onset diabetes after age 50 - especially alongside unexplained weight loss - should talk with their doctor about whether pancreatic cancer could be the cause.

If you or someone you love is experiencing one or more of these symptoms, please don't wait. Talk to your doctor and know that PanCAN Patient Services is here to help at 877-2-PANCAN. Learn more about the seven symptoms you should know and understanding your risk factors.

Progress Toward Earlier Detection

Knowing the signs matters because diagnosing pancreatic cancer in its earlier stages can significantly improve outcomes. When pancreatic cancer is found while it's still confined to the pancreas, the five-year survival rate is 44%. Once it has spread to distant organs, that number drops to 3%. Yet unlike breast, lung, colorectal, cervical and prostate cancers, there is still no screening test for pancreatic cancer, and there is not a standard surveillance program for people considered at elevated risk.

PanCAN is working to change that. Our Early Detection Initiative is a landmark study of people with new-onset diabetes. Enrollment was completed in January 2025, and the team is analyzing the data gathered at the one-year follow-up of more than 8,800 participants. The study is evaluating whether imaging at the time of diabetes onset can find pancreatic cancer in its earlier, more treatable stages. Participants are also providing blood samples that will help researchers search for blood-based biomarkers of early disease.

We're also encouraged by complementary approaches across the field:

  • Artificial intelligence (AI) and imaging. Researchers, including Dr. Ajit Goenka, who spoke at our Scientific Summit a few months ago, are developing AI tools that detect subtle abnormalities in abdominal CT scans that aren't visible to the human eye - which could help catch pancreatic cancer much earlier.
  • Prediction algorithms in health systems. PanCAN-funded work led by Dr. Bechien Wu is piloting algorithms that flag people at higher risk using information already in their medical records and, where appropriate, offering CT scans to determine if pancreatic cancer may be present.
  • Blood-based tests. Multi-cancer and pancreatic cancer-specific blood tests continue to advance, as I wrote about in April's Research Spotlight. Since then, two pancreatic cancer-specific blood tests available in the U.S. for people at elevated risk - Immunovia's PancreaSure® and ClearNote Health's Avantect® Pancreatic Cancer Test - have shared encouraging new data on detecting the disease at earlier stages.

Earlier detection alone isn't enough, though. We also need treatments that work - at every stage of disease.

A New Era in Treatment: RASONQUE

In August, the U.S. Food and Drug Administration (FDA) approved RASONQUE™ (daraxonrasib), the first RAS-targeting therapy that is broadly effective for pancreatic cancer, representing the most significant advancement we have ever seen in the fight against this disease.

KRAS mutations are changes in the RAS family of genes, and they drive more than 90% of pancreatic tumors. They act like a stuck "on" switch, telling cancer cells to keep growing. For decades, RAS was considered "undruggable." RASONQUE, a once-daily pill, blocks the activity of RAS proteins and shuts down those growth signals.

The results from the Phase III RASolute 302 clinical trial, presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, were remarkable:

  • Survival doubled. Patients with previously treated metastatic pancreatic cancer who received RASONQUE lived a median of 13.2 months, compared with 6.7 months for those who received chemotherapy.
  • Quality of life improved. Participants taking RASONQUE reported better quality of life and better pain control than those on chemotherapy.
  • Side effects were manageable. The most common were rash, mouth sores and diarrhea, and only about 1% of patients had to stop treatment permanently because of side effects.

RASONQUE is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. It is now considered the new standard of care for people with previously treated metastatic disease.

Even though RASONQUE was approved regardless of RAS mutation status, PanCAN continues to recommend biomarker testing for every patient. Testing can reveal other actionable changes, guide future treatment choices and open the door to clinical trials. If you have questions about whether RASONQUE may be right for you or a loved one, our Case Managers can help you prepare for that conversation with your healthcare team.

More Work to Do: Making RAS Inhibition Even More Effective

As exciting as this approval is, we need to remember that RASONQUE is only the beginning. Not every patient's tumor responds, and some tumors that respond at first can find ways around the drug and become resistant over time. Researchers are now working on several fronts to make RAS inhibition work better and for more people.

Moving earlier in the course of disease. The biggest gains from RAS inhibitors may come from using them earlier - when the goal is a cure. Even after successful surgery and chemotherapy, pancreatic cancer comes back for many people, often because a few cancer cells remain that may not show up on scans. The Phase III RASolute 304 trial is testing whether daraxonrasib, a daily pill, can keep those cells from growing back. After surgery and chemotherapy, participants are randomly assigned to take daraxonrasib or to receive today's standard care: regular checkups and scans to watch for the cancer's return. Researchers will compare how long people in each group live without their cancer coming back, a measure called disease-free survival.

Finding the right combinations and sequences. Researchers are studying how to pair RAS inhibitors with chemotherapy, other targeted therapies and immunotherapy - and the best order in which to give them.

Understanding and overcoming resistance. Several PanCAN-funded scientists, including recipients of our 2026 Research Recovery Grants, are studying in the lab how tumors become resistant to RAS-targeting drugs - and how to overcome it.

Clinical trials are how every one of these questions gets answered - and how every treatment advance, including RASONQUE, reached patients. PanCAN recommends that people with pancreatic cancer consider clinical trials at every treatment decision. Our Case Managers conduct clinical trials searches using our Clinical Trial Finder to help patients find options that fit their situation.

All Together, We Can Turn Science into Survival

None of this progress happened by chance. RASONQUE exists because of decades of research into RAS biology - much of it supported, convened and championed by PanCAN and our community. Ten years ago, at a PanCAN Scientific Meeting, leading RAS experts debated whether RAS could ever be drugged. This year, that question has been answered for patients.

That's why I'm so proud of All Together We Can, PanCAN's five-year, $250 million campaign to accelerate breakthrough research, expand PanCAN Patient Services and strengthen the pancreatic cancer field. Our vision is simple and bold: to make survival the expectation, not the exception, for everyone diagnosed with this disease.

Your support makes it possible to:

  • Fund the scientists - early-career and established - who are solving resistance, testing new combinations and bringing RAS inhibitors to earlier stages of disease
  • Complete and build on our Early Detection Initiative so more people are diagnosed when surgery is still an option
  • Connect every patient and family with free, personalized support, including biomarker testing guidance and clinical trials searches

This Pancreatic Cancer Awareness Month, I hope you'll do three things: learn the risk factors and symptoms, share them with someone you love and make a gift to PanCAN before the end of the year. Every dollar brings us closer to the day when a pancreatic cancer diagnosis comes with real hope.

This Awareness Month truly does feel different - and with your help, the progress we're seeing today can lead to longer, better lives tomorrow. All together, we can turn science into survival.

Pancreatic Cancer Action Network Inc. published this content on November 18, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 18, 2026 at 14:48 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]